Observational Study of Acalabrutinib in Patients With Chronic Lymphocytic Leukaemia in the United Kingdom
← catalyst calendarNCT05557695 · readout in 225 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →. With UKCLL Forum.
Phase
—
Status
Recruiting
Study type
Observational
Enrollment
350estimated
Sites
29
Country
United Kingdom
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-10-17 | actual | When the study began enrolling |
| Primary completion | 2027-04-01 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-04-01 | estimated | The whole study's end, after follow-up |
| First posted | 2022-09-28 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-02 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Chronic Lymphocytic Leukemia, CLL
Intervention
- Drug: Acalabrutinib — also filed as Calquence
Primary outcomes
what the primary-completion date above is the date OFReal-world progression free survival (rwPFS)
measured 12 months
Real-world progression free survival (rwPFS)
measured 24 months
Real-world progression free survival (rwPFS)
measured 36 months
Real-world progression free survival (rwPFS)
measured 48 months
Real-world progression free survival (rwPFS)
measured 60 months
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed